Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omecamtiv Mecarbil in chronic heart failure with reduced ejection fraction
CTR20170763Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF), sponsored by Amgen. Started Jan 2018; status: completed.
02
Drugs
omecamtiv mecarbil
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on CTR20170763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170763.